Search

Displaying results 2411 - 2420 of 7498 in total
  1. Drug

    Armodafinil

    go.drugbank.com/drugs/DB06413
    ApprovedInvestigational

    Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. … Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep

  2. Drug

    Dexketoprofen

    go.drugbank.com/drugs/DB09214
    ApprovedInvestigationalWithdrawn

    Dexketoprofen is a non-steroidal anti-inflammatory drug. It is available in the various countries in Europe, Asia and Latin America.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic
  3. Drug

    Vilobelimab

    go.drugbank.com/drugs/DB16416
    ApprovedInvestigational

    The drug is not yet fully approved for this condition.[L45849] … Vilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of human C5a with high affinity.

  4. Drug

    Secobarbital

    go.drugbank.com/drugs/DB00418
    ApprovedVet approved

    Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties.

  5. Drug

    Potassium chloride

    go.drugbank.com/drugs/DB00761
    ApprovedInvestigationalWithdrawn

    products containing potassium chloride that supply 100 mg or more of potassium per dosage unit, except for controlled-release dosage forms and those products formulated for preparation of solution prior to

    Mixtures: Dextrose and Electrolyte No. 75, Super Daily No 2
  6. Drug

    Guvacine

    go.drugbank.com/drugs/DB08848
    Experimental

    It is an experimental drug with no approved indication. Experimental studies are still being investigated to determine all of the physiological effects and mechanisms of action of guvacine. … Currently it has been determined that guvacine is a specific GABA reuptake inhibitor with no significant affinity at GABA receptors.

  7. Drug

    Interferon alfa-2a

    go.drugbank.com/drugs/DB00034
    ApprovedInvestigationalWithdrawn

    An oral form is being developed by Amarillo Biosciences. … This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.

  8. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    [A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms. … contribute to the pathophysiology of Alzheimer's Disease (AD).

  9. Drug

    Efgartigimod alfa

    go.drugbank.com/drugs/DB15270
    ApprovedInvestigational

    Myasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction … Efgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis.

  10. Drug

    Propylthiouracil

    go.drugbank.com/drugs/DB00550
    Approved

    Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism.